文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

伏诺拉生治疗症状性胃食管反流病或糜烂性食管炎安全性的整合分析

Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro-Oesophageal Reflux Disease or Erosive Oesophagitis.
PubMed 文献 · Aliment Pharmacol Ther · 2024-12-25

本整合分析纳入14项多国临床试验,比较伏诺拉生(n=5318)、兰索拉唑(n=1925)或埃索美拉唑(n=86)及安慰剂(n=779)的安全性,并补充2014年12月26日至2023年12月25日的上市后安全性数据。伏诺拉生耐受性良好,其临床试验与上市后安全性数据一致,治疗中出现的不良事件与质子泵抑制剂(PPI)相当。

要点

  • 鼻咽炎是唯一在至少5.0%患者中报告的不良事件:伏诺拉生6.94%、PPI 5.07%、安慰剂4.49%。
  • 严重不良事件每100人年发生率:伏诺拉生10.39、PPI 10.65、安慰剂1.69。
  • 伏诺拉生组血清胃泌素平均水平高于兰索拉唑组,但停药后4周内恢复正常。

核心结论

  • 伏诺拉生耐受性良好,其临床试验与上市后安全性数据一致,治疗中出现的不良事件与PPI对照药相当。

研究设计与样本

  • 整合分析纳入14项在多国开展的伏诺拉生成人临床试验,伏诺拉生组n=5318、兰索拉唑或埃索美拉唑对照组n=1925/86、安慰剂组n=779。
  • 伏诺拉生平均暴露2068人年,兰索拉唑或埃索美拉唑平均暴露751人年,安慰剂平均暴露59人年。
  • 同时提供2014年12月26日(日本上市日)至2023年12月25日的上市后安全性数据。

主要发现

  • 鼻咽炎是唯一在至少5.0%患者中报告的不良事件:伏诺拉生6.94%、PPI 5.07%、安慰剂4.49%。
  • 严重不良事件每100人年发生率:伏诺拉生10.39、PPI 10.65、安慰剂1.69。
  • 伏诺拉生组和兰索拉唑组各有1例患者诊断为胃癌。
  • 伏诺拉生组血清胃泌素平均水平高于兰索拉唑组,但停药后4周内恢复正常。
  • 肝酶升高不常见且幅度低,伏诺拉生与PPI之间无差异;共4例死亡,均认为与研究药物无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with erosive oesophagitis, and those with persistent symptomatic non-erosive gastro-oesophageal reflux disease, require long-term maintenance treatment with acid-suppressing agents. AIM: To evaluate the safety of vonoprazan, a potassium-competitive acid blocker, in an integrated analysis of data from clinical trials in adults. METHODS: We included 14 clinical trials of vonoprazan conducted in multiple countries. Mean duration of exposure in person-years to vonoprazan (n = 5318) was 2068, to comparators lansoprazole (n = 1925) or esomeprazole (n = 86) was 751, and to placebo (n = 779) was 59. We report adverse events, serum gastrin, and liver enzyme levels as the main outcomes. Post-marketing safety data from December 26, 2014 (date of commercialisation in Japan) to December 25, 2023, are also provided. RESULTS: Nasopharyngitis was the only adverse event reported by at least 5.0% of patients (6.94% vonoprazan, 5.07% proton pump inhibitor (PPI), 4.49% placebo). Incidence rates per 100 person-years for serious adverse events were 10.39 for vonoprazan, 10.65 for PPIs, and 1.69 for placebo. One patient each on vonoprazan and lansoprazole was diagnosed with gastric cancer. Mean serum gastrin levels were higher on vonoprazan than lansoprazole but normalised by 4 weeks after discontinuation. Elevated liver enzyme levels were infrequent and of low magnitude with no differences between vonoprazan and PPIs. There were four deaths; none was considered related to study drug. CONCLUSIONS: Vonoprazan was well tolerated. Its safety profile from both clinical trial and post-marketing data were consistent and comparable to that of its PPI comparators with respect to treatment-emergent adverse events.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Howden CW, Katz P, DeVault KR, et al. Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro-Oesophageal Reflux Disease or Erosive Oesophagitis. Aliment Pharmacol Ther. 2024. PMID: 39720884. doi:10.1111/apt.18458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。